The Bull Rankings scorecard — our quality-growth score is 76.1 / 100, built from three pillars scored 0–100: Quality 60, Growth 89, Value 83 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 21% a year next year, fading to 4% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Aveanna Healthcare Holdings is a value play with a growth engine that the market has undervalued. The P/E of 9.7 places AVAH in the cheapest decile of Healthcare, a clear sign that price is still far below earnings. Coupled with a 19.5 % revenue growth and a 10.6 % profit margin, the stock trades at a discount to peers that are delivering similar or lower growth. Our model’s Quality‑Growth score of 76.1/100, anchored by a Growth pillar of 89, confirms that the company’s trajectory is the strongest driver of upside. The only soft spot is a Quality score of 60, which reflects the high debt‑to‑equity of 5.23, but that is a manageable risk given the company’s free‑cash‑flow of $154 m and a ROE of 95.6 %. In short, AVAH is a low‑priced, high‑growth business that can deliver a solid return on capital.
What the business actually is
Aveanna operates a home‑care platform that keeps patients out of expensive institutional settings. Its revenue engine is split into three segments:
- Private Duty Services (PDS) – in‑home skilled nursing for medically complex children and adults, plus school‑based nursing.
- Home Health & Hospice (HHH) – traditional home‑health nursing and hospice care.
- Medical Solutions (MS) – ancillary medical services that support the other two lines.
The PDS segment is the growth engine, driving the 19.5 % YoY revenue rise seen in the latest quarter. By keeping patients in their homes, Aveanna reduces hospital readmissions and leverages a scalable, technology‑enabled care model that can be replicated across the U.S. market.
Why it can (or can't) keep compounding
The moat lies in the patient‑centered care delivery platform. Once a patient is enrolled, the company builds a long‑term relationship, generating recurring revenue and high switching costs for competitors. The 10.6 % profit margin shows that the company can extract value from its services while maintaining quality. A ROE of 95.6 % indicates that capital is being deployed efficiently, and the $154 m free‑cash‑flow provides a buffer against the high debt‑to‑equity ratio. The strongest model signal, “Diluting shareholders,” warns that share buybacks or dividends could erode value, but the company’s current cash generation suggests it can sustain operations without immediate dilution. Competitors would need to replicate the integrated platform and patient relationships, a process that takes years and significant capital.
The valuation question
The market’s P/E of 9.7 is the cheapest in Healthcare, yet the reverse‑DCF implied growth of 21 % in year 1, tapering to 4 % by year 10, is in line with the trailing revenue growth of 19.5 %. This alignment means the price already prices in a realistic growth trajectory; it is neither overly optimistic nor pessimistic. The PEG ratio of 0.96 confirms that earnings growth is expected to keep pace with revenue expansion. With a 95.6 % ROE and a 10.6 % margin, the company can sustain the implied growth without needing to raise additional debt. Therefore, the valuation is a fair reflection of current fundamentals, leaving room for upside if the growth engine accelerates or if the debt load eases.
The bear case
The primary risk is the high debt‑to‑equity of 5.23. If interest rates climb or if the company cannot refinance its debt, cash flow could be strained, forcing cost cuts or asset sales that would hurt margins and growth. A single figure that supports this is the 5.23 debt‑to‑equity ratio, which is well above the industry average for home‑care providers. Additionally, the “Diluting shareholders” signal suggests that future capital structure changes could erode shareholder value if the company opts for more equity or if it issues new shares to service debt.
What would change our mind
- Debt‑to‑equity falling below 3.0 – a significant reduction would lift the Quality pillar and remove the dilution concern.
- Revenue growth slipping below 15 % YoY – a slowdown would undermine the Growth pillar and weaken the valuation justification.
- Profit margin dropping below 8 % – a margin erosion would signal operational stress and erode the company’s ability to generate free cash flow.
If any of these thresholds were breached, the current thesis would shift from a value‑growth blend to a more cautious stance.